

## **NA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2023-01-01 | 194 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

North America breast cancer diagnostics market is projected to register a CAGR of 9.5% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

### **Market Segmentation:**

North America Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America breast cancer diagnostics market are:

- Increasing breast cancer patients among the women population as well as men
- Rise in technological advancement for breast cancer diagnostic

### **Market Players**

The key market players operating in the North America breast cancer diagnostics market are:

- F-Hoffmann La Roche Ltd.
- Siemens Healthcare GmbH
- General Electric
- Koninklijke Philips N.V.
- FUJIFILM Corporation
- Abbott
- Hologic, Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## **Table of Contents:**

TABLE OF CONTENTS	
1 INTRODUCTION	48
1.1 OBJECTIVES OF THE STUDY	48
1.2 MARKET DEFINITION	48
1.3 OVERVIEW OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET	48
1.4 CURRENCY AND PRICING	50
1.5 LIMITATIONS	50
1.6 MARKETS COVERED	50
2 MARKET SEGMENTATION	54
2.1 MARKETS COVERED	54
2.2 GEOGRAPHICAL SCOPE	55
2.3 YEARS CONSIDERED FOR THE STUDY	56
2.4 DBMR TRIPOD DATA VALIDATION MODEL	57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	60
2.6 MULTIVARIATE MODELLING	61
2.7 MARKET END USER COVERAGE GRID	62
2.8 TEST TYPE LIFELINE CURVE	63
2.9 DBMR MARKET POSITION GRID	64
2.10 VENDOR SHARE ANALYSIS	65
2.11 SECONDARY SOURCES	66
2.12 ASSUMPTIONS	66
3 EXECUTIVE SUMMARY	67
4 PREMIUM INSIGHTS	69
4.1 PESTEL ANALYSIS	70
4.2 PORTER'S 5 FORCES	71
5 EPIDEMIOLOGY	72
6 INDUSTRIAL INSIGHTS	73
7 REGULATORY FRAMEWORK	74
8 MARKET OVERVIEW	76
8.1 DRIVERS	78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH	78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER	78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH	79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER	79
8.2 RESTRAINTS	80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS	80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS	80
8.3 OPPORTUNITIES	81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT	81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS	81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER	82
8.4 CHALLENGES	82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE	82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER	83
9 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE	84
9.1 OVERVIEW	85

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.2 IMAGING	88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES	89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)	90
9.2.1.2 ANALOG MAMMOGRAPHY	90
9.2.1.3 3D BREAST TOMOSYNTHESIS	90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)	90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)	90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY	90
9.2.1.7 OTHERS	90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES	90
9.2.2.1 OPTICAL IMAGING	91
9.2.2.2 BREAST ULTRASOUND	91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)	91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)	91
9.2.2.5 BREAST THERMOGRAPHY	92
9.2.3 BIOPSY	92
9.2.3.1 SURGICAL BIOPSY	93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY	93
9.2.3.3 CORE NEEDLE BIOPSY	93
9.2.3.4 IMAGE-GUIDED BIOPSY	93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY	94
9.2.4 GENOMIC TEST	94
9.2.4.1 MOLECULAR TESTING	95
9.2.4.1.1 PD-L1	96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)	96
9.2.4.1.3 NTRK GENE FUSIONS	96
9.2.4.1.4 PI3KCA GENE MUTATION	96
9.2.4.2 MAMMAPRINT	96
9.2.4.3 ONCOTYPE DX	96
9.2.4.4 OTHERS	96
9.3 BLOOD TEST	97
9.4 OTHERS	98
10 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE	99
10.1 OVERVIEW	100
10.2 INVASIVE DUCTAL CARCINOMA	103
10.3 DUCTAL CARCINOMA IN SITU	103
10.4 INFLAMMATORY BREAST CANCER	104
10.5 METASTATIC BREAST CANCER	105
11 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER	106
11.1 OVERVIEW	107
11.2 HOSPITALS	109
11.3 DIAGNOSTICS CENTERS	110
11.4 CLINICS	111
11.5 RESEARCH & ACADEMIC INSTITUTES	111
11.6 OTHERS	112
12 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	114
12.1 OVERVIEW	115

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

12.2 DIRECT TENDER	118
12.3 RETAIL SALES	118
12.4 OTHERS	119
13 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION	120
13.1 NORTH AMERICA	121
13.1.1 U.S.	129
13.1.2 CANADA	135
13.1.3 MEXICO	141
14 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	147
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	147
15 SWOT ANALYSIS	148
16 COMPANY PROFILE	149
16.1 HOLOGIC, INC.	149
16.1.1 COMPANY SNAPSHOT	149
16.1.2 REVENUE ANALYSIS	149
16.1.3 COMPANY SHARE ANALYSIS	150
16.1.4 PRODUCT PORTFOLIO	150
16.1.5 RECENT DEVELOPMENTS	151
16.2 SIEMENS HEALTHCARE GMBH	152
16.2.1 COMPANY SNAPSHOT	152
16.2.2 REVENUE ANALYSIS	153
16.2.3 COMPANY SHARE ANALYSIS	153
16.2.4 PRODUCT PORTFOLIO	154
16.2.5 RECENT DEVELOPMENTS	154
16.3 F. HOFFMANN- LA ROCHE LTD	155
16.3.1 COMPANY SNAPSHOT	155
16.3.2 REVENUE ANALYSIS	155
16.3.3 COMPANY SHARE ANALYSIS	156
16.3.4 PRODUCT PORTFOLIO	156
16.3.5 RECENT DEVELOPMENTS	157
16.4 KONINKLIJKE PHILIPS N.V.	158
16.4.1 COMPANY SNAPSHOT	158
16.4.2 REVENUE ANALYSIS	158
16.4.3 COMPANY SHARE ANALYSIS	159
16.4.4 PRODUCT PORTFOLIO	159
16.4.5 RECENT DEVELOPMENTS	160
16.5 ABBOTT	161
16.5.1 COMPANY SNAPSHOT	161
16.5.2 REVENUE ANALYSIS	161
16.5.3 COMPANY SHARE ANALYSIS	162
16.5.4 PRODUCT PORTFOLIO	162
16.5.5 RECENT DEVELOPMENTS	162
16.6 ABACUS ALS	163
16.6.1 COMPANY SNAPSHOT	163
16.6.2 PRODUCT PORTFOLIO	163
16.6.3 RECENT DEVELOPMENTS	163
16.7 BD	164

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

16.7.1 COMPANY SNAPSHOT	164
16.7.2 REVENUE ANALYSIS	164
16.7.3 COMPANY SHARE ANALYSIS	165
16.7.4 PRODUCT PORTFOLIO	165
16.7.5 RECENT DEVELOPMENTS	165
16.8 BIOCEPT, INC.	166
16.8.1 COMPANY SNAPSHOT	166
16.8.2 REVENUE ANALYSIS	166
16.8.3 PRODUCT PORTFOLIO	167
16.8.4 RECENT DEVELOPMENTS	167
16.9 BIOMERIEUX	168
16.9.1 COMPANY SNAPSHOT	168
16.9.2 REVENUE ANALYSIS	168
16.9.3 PRODUCT PORTFOLIO	169
16.9.4 RECENT DEVELOPMENTS	169
16.10 BIO-RAD LABORATORIES, INC.	170
16.10.1 COMPANY SNAPSHOT	170
16.10.2 REVENUE ANALYSIS	170
16.10.3 PRODUCT PORTFOLIO	171
16.10.4 RECENT DEVELOPMENT	171
16.11 CEPHEID	172
16.11.1 COMPANY SNAPSHOT	172
16.11.2 REVENUE ANALYSIS	172
16.11.3 PRODUCT PORTFOLIO	173
16.11.4 RECENT DEVELOPMENT	173
16.12 EXACT SCIENCES CORPORATION	174
16.12.1 COMPANY SNAPSHOT	174
16.12.2 REVENUE ANALYSIS	174
16.12.3 COMPANY SHARE ANALYSIS	175
16.12.4 PRODUCT PORTFOLIO	175
16.12.5 RECENT DEVELOPMENTS	176
16.13 FUJIFILM CORPORATION	177
16.13.1 COMPANY SNAPSHOT	177
16.13.2 REVENUE ANALYSIS	177
16.13.3 PRODUCT PORTFOLIO	178
16.13.4 RECENT DEVELOPMENT	178
16.14 GENERAL ELECTRIC	179
16.14.1 COMPANY SNAPSHOT	179
16.14.2 REVENUE ANALYSIS	179
16.14.3 PRODUCT PORTFOLIO	180
16.14.4 RECENT DEVELOPMENTS	180
16.15 ILLUMINA, INC.	181
16.15.1 COMPANY SNAPSHOT	181
16.15.2 REVENUE ANALYSIS	181
16.15.3 PRODUCT PORTFOLIO	182
16.15.4 RECENT DEVELOPMENTS	182
16.16 MYRIAD GENETICS, INC.	183

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

16.16.1 COMPANY SNAPSHOT	183
16.16.2 REVENUE ANALYSIS	183
16.16.3 PRODUCT PORTFOLIO	184
16.16.4 RECENT DEVELOPMENT	184
16.17 NANOSTRING.	185
16.17.1 COMPANY SNAPSHOT	185
16.17.2 REVENUE ANALYSIS	185
16.17.3 PRODUCT PORTFOLIO	186
16.17.4 RECENT DEVELOPMENT	186
16.17.5 RECENT DEVELOPMENT	186
16.18 ONCOSTEM.	187
16.18.1 COMPANY SNAPSHOT	187
16.18.2 PRODUCT PORTFOLIO	187
16.18.3 RECENT DEVELOPMENT	187
16.19 PROVISTA DIAGNOSTICS.	188
16.19.1 COMPANY SNAPSHOT	188
16.19.2 PRODUCT PORTFOLIO	188
16.19.3 RECENT DEVELOPMENT	188
16.20 THERMO FISHER SCIENTIFIC INC.	189
16.20.1 COMPANY SNAPSHOT	189
16.20.2 REVENUE ANALYSIS	189
16.20.3 PRODUCT PORTFOLIO	190
16.20.4 RECENT DEVELOPMENT	190
17 QUESTIONNAIRE	191
18 RELATED REPORTS	194

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## NA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 194 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-08"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com